CytomX Therapeutics Inc.

0.61
0.03 (5.17%)
At close: Apr 02, 2025, 3:59 PM
0.59
-2.74%
After-hours: Apr 02, 2025, 07:55 PM EDT
5.17%
Bid 0.56
Market Cap 48.6M
Revenue (ttm) n/a
Net Income (ttm) n/a
EPS (ttm) 0.38
PE Ratio (ttm) 1.6
Forward PE -2.01
Analyst Hold
Ask 0.65
Volume 875,709
Avg. Volume (20D) 1,834,423
Open 0.58
Previous Close 0.58
Day's Range 0.56 - 0.62
52-Week Range 0.56 - 5.85
Beta 1.04

About CTMX

CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for the treatment of breast cancer; CX-2029 that is in Phase II clinical trials for the treatme...

Industry Biotechnology
Sector Healthcare
IPO Date Oct 8, 2015
Employees 119
Stock Exchange NASDAQ
Ticker Symbol CTMX
Full Company Profile

Analyst Forecast

According to 6 analyst ratings, the average rating for CTMX stock is "Hold." The 12-month stock price forecast is $5.79, which is an increase of 854.19% from the latest price.

Stock Forecasts

Next Earnings Release

CytomX Therapeutics Inc. is scheduled to release its earnings on May 7, 2025, during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
3 weeks ago
+7.71%
CytomX Therapeutics shares are trading higher afte... Unlock content with Pro Subscription
4 months ago
+9%
CytomX Therapeutics shares are trading higher after the company reported better-than-expected Q3 financial results.